5.35  0.81 (17.84%)		06-26 16:00
Open: 4.5 High: 5.44 Volume: 8,153,625		Pre. Close: 4.54 Low: 4.47 Market Cap: 348(M)

Short term
Mid term
Targets	6-month :	6.35	1-year :	7.42
Resists	First :	5.44	Second :	6.35
Pivot price	3.91
Supports	First :	4.08	Second :	3.25
MAs	MA(5) :	4.53	MA(20) :	3.94
	MA(100) :	5.35	MA(250) :	4.08
MACD	MACD :	0	Signal :	-0.2
%K %D	K(14,3) :	92.2	D(3) :	91.5
RSI	RSI(14): 71.3
52-week	High :	7.44	Low :	1

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ZURA ] has closed It is unclear right now based on current values. 67.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	5.45 - 5.47	5.47 - 5.48
Low:	4.42 - 4.45	4.45 - 4.46
Close:	5.31 - 5.35	5.35 - 5.38

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Fri, 26 Jun 2026
Zura Bio Limited Class A Actuals & Estimates (NASDAQ:ZURA) - TradingView

Mon, 22 Jun 2026
Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options - Stock Titan

Mon, 22 Jun 2026
Zura Bio (ZURA) director receives grant of 51,000 stock options - Stock Titan

Mon, 22 Jun 2026
Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options - Stock Titan

Mon, 22 Jun 2026
Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price - Stock Titan

Wed, 03 Jun 2026
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	95 (M)
Shares Float	55 (M)
Held by Insiders	21.3 (%)
Held by Institutions	78.5 (%)
Shares Short	6,220 (K)
Shares Short P.Month	6,970 (K)

EPS	-1.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-25.4 %
Return on Equity (ttm)	-41 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.86
Qtrly Earnings Growth	0 %
Operating Cash Flow	-73 (M)
Levered Free Cash Flow	-48 (M)

PE Ratio	-4.91
PEG Ratio	0
Price to Book value	2.33
Price to Sales	0
Price to Cash Flow	-6.99

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.